RAB22A and osteosarcoma: Our group has recently reported that Rab22a‐NeoF1 fusion protein may be a promising target for osteosarcoma metastasis.[5, 6] We have previously showed that Rab22a‐NeoF1 fusion protein could be stabilized in cells treated with proteasome inhibitor MG132 plus lysosome inhibitor BafA1 (extended data Fig. 2a of ref. [7]), indicating that Rab22a‐NeoF1 fusion protein may be degraded by proteasome and/or lysosome.